Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $230.1 million.

  • Axsome Therapeutics' Total Current Liabilities rose 83.65% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.3 million, marking a year-over-year increase of 83.65%. This contributed to the annual value of $230.1 million for FY2024, which is 65.72% up from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Total Current Liabilities is $230.1 million, which was up 65.72% from $138.9 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Total Current Liabilities registered a high of $230.1 million during FY2024, and its lowest value of $96.6 million during FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Total Current Liabilities value was $138.9 million (recorded in 2023), while the average stood at $155.2 million.
  • Data for Axsome Therapeutics' Total Current Liabilities shows a peak YoY spiked of 65.72% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Total Current Liabilities stood at $96.6 million in 2022, then skyrocketed by 43.80% to $138.9 million in 2023, then skyrocketed by 65.72% to $230.1 million in 2024.